GlaxoSmithKline : Un ralentissement notable au T2, un rebond attendu au T3
>Des tendances marquées sans pour autant être surprenantes - GSK publiait hier en séance ses résultats du T2 qui ont été marqués, à l’instar de ses pairs, par un ralentissement notable et attendu des ventes du groupe. Deux éléments ressortent de ce T2 : le déstockage mais aussi un ralentissement significatif du Vaccin et notamment de Shingrix (-19% tcc), et Meningitis (-29% tcc). Ce ralentissement dans la franchise Vaccin est venu sensiblement impacter la marge du gr...GlaxoSmithKline is a global healthcare company. Co.'s segments include: Pharmaceuticals; Vaccines; and Consumer Healthcare. The Pharmaceuticals segment is focused on developing new medicines in respiratory, HIV, oncology and immuno-inflammation, with discovery research exploring these and other areas. The Vaccines segment has a portfolio and pipeline of vaccines to help protect people throughout life. Co. delivers vaccines to people living in over 160 countries. The Consumer Healthcare segment develops and markets consumer-preferred brands in oral health, pain relief, respiratory, nutrition/gastro-intestinal and skin health.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.